Effect of supplementation in treatment of polycystic ovary syndrome

Effects of zinc supplementation on insulin resistance and lipid factors in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201406075623N19

Enrollment

Registered

2014-07-16

Start date

2014-07-07

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention group: Zinc tablet, 50 mg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo tablet, daily, for 8 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Women aged 18-40 years

Exclusion criteria

Exclusion criteria: Menopause Consume zinc supplements in the last 3 months Smokers Pregnancy History of diseases including diabetes, liver, kidney and CVD. Thyroid disorders Hyperprolactinemia Cushing’s syndrome

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Insulin sensitivity. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;VLDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;VLDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026